Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice

Semin Liver Dis. 2019 Jul;39(3):381-394. doi: 10.1055/s-0039-1685519. Epub 2019 May 2.

Abstract

Drug-induced liver injury (DILI) is the leading cause of acute liver failure (ALF) in developed countries. The extremely variable phenotype of DILI, both in presentation and in severity, is one of the distinctive characteristics of the disease and one of the major challenges that hepatologists face when assessing hepatotoxicity cases. A new Hy's law that more accurately predicts the risk of ALF related to DILI has been proposed and validated. Other prognostic scoring algorithms for the early identification of DILI patients who may go on to develop ALF have been developed as it is of most clinical relevance to stratify patients for closer monitoring. Recent data indicate that acute DILI often presents a more prolonged resolution or evolves into chronicity at a higher frequency than other forms of acute liver injury. Risk factors for chronicity, specific phenotypes, and histological features are discussed in this study. Biomarkers to predict DILI outcome are in need.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / blood
  • Blood Coagulation Disorders / etiology
  • Chemical and Drug Induced Liver Injury / blood
  • Chemical and Drug Induced Liver Injury / complications*
  • Chemical and Drug Induced Liver Injury / pathology*
  • Chemical and Drug Induced Liver Injury, Chronic / blood
  • Chemical and Drug Induced Liver Injury, Chronic / complications
  • Chemical and Drug Induced Liver Injury, Chronic / etiology
  • Chemical and Drug Induced Liver Injury, Chronic / pathology
  • Drug Eruptions / etiology
  • Fatty Liver / etiology
  • Hepatic Encephalopathy / etiology
  • Humans
  • Liver Failure, Acute / etiology*
  • Phenotype
  • Risk Factors
  • Severity of Illness Index

Substances

  • Biomarkers